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Abstract
Objective: Statins are among the most prescribed drugs worldwide and their recently discovered anti-inflammatory effect
seems to have an important role in inhibiting proinflammatory cytokine production, chemokines expression and
counteracting the harmful effects of sepsis on the coagulation system. We decided to perform a meta-analysis of all
randomized controlled trials ever published on statin therapy in septic patients to evaluate their effect on survival and
length of hospital stay.
Data sources and study selection: Articles were assessed by four trained investigators, with divergences resolved by
consensus. BioMedCentral, PubMed, Embase and the Cochrane Central Register of clinical trials were searched for pertinent
studies. Inclusion criteria were random allocation to treatment and comparison of statins versus any comparator in septic
patients.
Data extraction and synthesis: Data from 650 patients in 5 randomized controlled studies were analyzed. No difference in
mortality between patients receiving statins versus control (44/322 [14%] in the statins group vs 50/328 [15%] in the control
arm, RR = 0.90 [95% CI 0.65 to 1.26], p = 0.6) was observed. No differences in hospital stay (p = 0.7) were found.
Conclusions: Published data show that statin therapy has no effect on mortality in the overall population of adult septic
patients. Scientific evidence on statins role in septic patients is still limited and larger randomized trials should be performed
on this topic.
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Introduction
Discovered by Akira Endo in 1970s [1] and taken by more than
20 millions of Americans, 3-hydroxy-3-methylglutaryl coenzyme A
(HMG-CoA) reductase inhibitors (statins) are, nowadays, the most
prescribed drugs in the world.
They are widely used in medical practice as cholesterol-lowering
agents and their beneficial effects on vascular diseases, reducing
the risk of myocardial infarction and prolonging life, have been
demonstrated in several clinical trials [2,3], even if statin therapy
does not eliminate cardiovascular risk [4,5]. In the last few years a
beneficial effect of statins on the outcome of other severe disease
such as cancer and infections [6,7] has been hypothesized. This
‘‘pleiotropic’’ effect seems to be related to their potential
modulation of both innate and adaptative immune system and
anti-inflammatory effects [8–10]. By inhibiting tissue factor
expression and reducing prothrombin fragment levels [11] and
by strongly increasing the expression of thrombomodulin [12],
statins seem to have an important role in counteracting the
harmful effects of sepsis on the coagulation system. Moreover
numerous studies suggest inhibitory effects of statins on proin-
flammatory cytokine production (Interferon-c, tumor necrosis
factor-a, interleukin (IL-1b and IL-6) and on chemokines
(chemokines CCL2, CCL7, CCL13, CCL18, CXCL1) expression
[13–15]. Accordingly, many observational studies suggested that
statin treatment may be associated with a better prognosis in
severe bacterial infections.
Since new randomized trials have recently appeared on this
topic [16–18] we decided to perform a meta-analysis of all
randomized controlled trials ever performed on statin therapy in
septic patients to evaluate its effect on survival and length of
hospital stay.
Methods
Search Strategy
Pertinent studies were independently searched in BioMedCen-
tral, PubMed, Embase, and the Cochrane Central Register of
clinical trials (updated September 1st 2013) by four trained
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investigators. The full PubMed search strategy aimed to include
any randomized study ever performed in humans with statins in
sepsis or infectious diseases and is presented in the supplemental
material. In addition, backward snowballing was employed (i.e.,
scanning of references of retrieved articles and pertinent reviews)
and international experts were contacted for further studies. No
language restriction was imposed.
Study Selection
References obtained from database and literature searches were
first independently examined at a title/abstract level by four
investigators, with divergences resolved by consensus, and then, if
potentially pertinent, retrieved as complete articles. The following
inclusion criteria were used for potentially relevant studies: random
allocation to treatment (statins versus any comparator with no
restrictions on dose or time of administration) and studies involving
septic patients. The exclusion criteria were: duplicate publications
either acknowledged or not (in this case we referred to the first article
published while retrieved data from the article with the longest
follow-up available), non-adult patients and lack of data on main
outcomes. Compliance to selection criteria and selected studies for
the final analysis were independently assessed by two investigators,
with divergences finally resolved by consensus. Primary outcome was
mortality at the longest follow-up available in each single study.
Secondary outcome was hospital length of stay (HLOS).
Internal Validity and Risk of Bias Assessment
The internal validity and risk of bias of included trials was
appraised by two independent reviewers according to Cochrane
Collaboration methods [19], with divergences resolved by
consensus. Publication bias was assessed by visually inspecting
funnel plots (Figures S1 and S2).
Data Analysis and Synthesis
Computations were performed with Review Manager version
5.2. Hypothesis of statistical heterogeneity was tested by means of
Cochran Q test, with statistical significance set at the two-tailed
0.10 level, whereas extent of statistical consistency was measured
with I2, defined as 100% X (Q-df)/Q, where Q is Cochran’s
heterogeneity statistic and df the degrees of freedom. Binary
outcomes were analysed to compute the individual and pooled risk
ratio (RR) with pertinent 95% confidence interval (CI), by means
of the same models as just described. Binary outcomes from
individual studies were analysed to compute individual and pooled
risk ratio (RR) with pertinent 95% confidence interval (CI), by
means of inverse variance method and with a random-effect model
(which better accommodates clinical and statistical variations).
Mean differences (MD) and 95% confidence intervals were
computed for continuous variables using the same models as just
described. Sensitivity analyses were performed by sequentially
removing each study and reanalysing the remaining dataset
(producing a new analysis for each study removed) and by
analysing only data from studies with low risk of bias. Statistical
significance was set at the two-tailed 0.05 level for hypothesis
testing. Unadjusted p values are reported throughout. This study
was performed in compliance with The Cochrane Collaboration
and Preferred Reporting Items for Systematic Reviews and Meta-
Analyses guidelines [19–22] (Checklist S1).
Results
Study Characteristics
Database searches, snowballing, and contacts with experts
yielded a total of 257 articles. Excluding 245 non-pertinent titles or
abstracts, we retrieved in complete form and assessed 12 studies
according to the selection criteria (Figure 1). Seven studies were
Figure 1. Flow diagram for selection of articles.
doi:10.1371/journal.pone.0082775.g001
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further excluded because of our prespecified exclusion criteria:
three studies were excluded because they were not randomized
[23–25], three because including not only septic patients [26–28]
and one because the data were included in a previous publication
[29].
The five included manuscripts randomized 650 patients, 322 to
statins and 328 to control (Table 1). One of the included trials was
multicentre [17]. Clinical heterogeneity was mostly due to setting,
statin used, study drug dosage and follow-up duration. Indeed, one
trial used statins in severe sepsis [17], three in septic patients in a
general ward setting [16,19,30] and one in sepsis due to
pneumonia [31]. Different statins were used: atorvastatin in four
trials [16–18,31] and simvastatin in one trial [30]. Study quality
appraisal indicated that four trials were of high quality while one
study [31] was published as abstract only (Table 2). The identified
comparator was placebo in four trials [16–18,30] while in one trial
[31] it was not clearly defined.
Quantitative Data Synthesis
No difference in mortality (Figure 2) was recorded at the longest
follow-up available (44/322 [14%] in the statins group vs 50/328
[15%] in the control group, RR=0.90 [95% CI 0.65 to 1.26], p
for effect = 0.6, p for heterogeneity 0.8, I2 = 0% with 5 studies
included) with results confirmed at sensitivity analyses (Table 3).
Switching from random to fixed effects model made no difference
to the estimates. Visual inspection of funnel plot did not identify a
skewed or asymmetrical shape, excluding the presence of small
publication bias (Figure S1).
Each single study showed improvements in secondary endpoints
such as organ dysfunction, ventilator associated pneumonia or
inflammatory markers (Table 1) but this did not translate in
difference in hospital stay (SMD=20.24 [21.59 to 1.12] days, p
for effect = 0.7, p for heterogeneity 0.20, I2 = 36% with 4 studies
and 583 patients included). Visual inspection of funnel plot did not
identify a skewed or asymmetrical shape, excluding the presence of
small publication bias (Figure S2).
Discussion
Our meta-analysis shows that statins therapy does not influence
mortality in septic patients. This is the first meta-analysis ever
performed on this topic that includes only randomized clinical
trials.
In recent years the use of statins in critically ill patients has
particularly attracted intensive care physicians but publications
had discordant results probably because of the high heterogeneity
of the included studies and because of the poor quality of non-
randomized trials.
The growing interest in the use of statins in sepsis is derived
from some experimental and subsequent clinical studies demon-
strating a beneficial effect of statins during acute respiratory
distress syndrome, acute lung injury or sepsis. In fact two
experimental animal studies showed an improved survival in
animals treated with statins before induction of sepsis [32,33]. The
results of many subsequent clinical studies were summarized in an
interesting meta-analysis supporting the hypothesis of a protective
effect of statins during sepsis [34]. This previous systematic review
included 20 clinical trials, all but one [26] observational, 15 of
which showing a decreased mortality rate in patients receiving
statins.
Chopra et al. [35], in a recent meta-analysis on the effects of
statins on mortality of patients with community-acquired pneu-
monia, showed that statin use was associated with an improved 30-
day survival, but this beneficial effect weakened in important
subgroups of patients and in high-quality methodological studies.
Trying to understand the actual role of statin therapy in
critically ill patients is mandatory. While it’s true that statins are
probably the most prescribed drugs in the world [36] and a
potential aid in reducing mortality in septic patients would be
desirable, the impact of their possible side effects in critically ill
patients should not be underestimated.
It is well known that sepsis is characterized by systemic
inflammation and impairment of the coagulation cascade [37]
and the pleiotropic effect of statins in this setting may, therefore, be
beneficial. Instead, what is not yet well known, is the incidence and
severity of statins side effects in critically ill patients. Their most
severe side effects, myopathy and rhabdomyolysis, are really rare
in the generally population [38], but it can’t be excluded that their
incidence and severity could be higher in compromised patients,
with a theoretical consequent detrimental effect on survival.
Our study found no evidence of a beneficial effect of statins
therapy on mortality in septic patients. The strength of our
analysis is that it includes only randomized clinical trials, the
preferred study design to assess the efficacy of a medical treatment.
On the other hand, however, the few included studies and the
small number of patients in these RCTs, don’t allow to draw
definitive conclusions on the real role of statins therapy in critically
ill patients.
Limitations
We acknowledge that this study has several limitations. First of
all it includes a limited number of small clinical trials, all but one
Figure 2. Forest Plot for mortality.
doi:10.1371/journal.pone.0082775.g002
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monocentric. Moreover studies present clinical heterogeneity
(setting, statin used, study drug dosage and follow-up duration).
Despite the pooled sample size (650 patients in five RCTs), we
cannot conclude whether the lack of a statistically significant
improvement in survival was due to inadequate power or due to a
true lack of beneficial effects of statins. In fact, with 650 patients
and a mortality rate of 15% in the control group, statins had to
reduce mortality by an implausible 50% (from 15% to 7.5%) to
obtain a statistically significant result. Nonetheless, the results of
our meta-analysis are useful for future researchers in that,
assuming a 15% mortality in the control group, a plausible 25%
reduction in mortality in the statins group (from 15% to 11.25%)
and a power of 80% you have to randomize 1325 patient per
group to have an adequately powered RCT. Moreover, given the
small number of studies, we were unable to evaluate the role of
statins in specific subsettings or on other relevant clinical outcomes
such as length of intensive care unit stay or length of mechanical
ventilation.
Conclusions
Even if all randomized data published so far show that statins
therapy has beneficial effect on secondary outcomes or inflam-
matory markers, this meta-analysis of randomized trials showed no
effect of statins on mortality or length of hospital stay in the overall
population of adult septic patients. Scientific evidence on statin
role in septic patients is still limited and larger randomized clinical
trials should be performed on this topic.
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